Loading clinical trials...
Loading clinical trials...
An Open-label, Single-arm, Multi-center, Phase II Clinical Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer
Conditions
Interventions
MRG002
Locations
36
China
Anhui provincial Cancer Hospital
Hefei, Anhui, China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing hospital
Beijing, Beijing Municipality, China
Beijing Chao-Yang Hospital，Capital Medical University
Beijing, Beijing Municipality, China
The Fifth Medical Center of the PLA
Beijing, Beijing Municipality, China
Start Date
April 20, 2021
Primary Completion Date
June 1, 2022
Completion Date
September 1, 2022
Last Updated
December 14, 2021
NCT05923190
NCT01552434
NCT05845814
NCT00365157
NCT07386847
NCT03590054
Lead Sponsor
Shanghai Miracogen Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions